Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Akebia Therapeutics

Status and phase: Completed; Phase 2

Conditions: Anemia; Dialysis Dependent Chronic Kidney Disease

Treatments: Drug: Placebo; Drug: Vadadustat

Study type: Interventional

Funder types: Industry

Identifiers

NCT03054350

AKB-6548-CI-0022

Details and patient eligibility

About

This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of orally administered vadadustat in Japanese participants with anemia secondary to Dialysis-dependent Chronic Kidney Disease (DD-CKD).

Enrollment: 60 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female Japanese participants ≥20 years of age
• Receiving chronic maintenance hemodialysis for end-stage kidney disease
• Hemoglobin (Hb) <10.0 grams per deciliter (g/dL)

Exclusion criteria

• Anemia due to a cause other than chronic kidney disease (CKD) or presence of active bleeding or recent blood loss
• Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
• Red blood cell transfusion within 4 weeks prior to or during screening
• Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 4 patient groups, including a placebo group

Vadadustat, Dose 1

Experimental group

Description:

Daily oral dose

Treatment:

Drug: Vadadustat

Vadadustat, Dose 2

Experimental group

Description:

Daily oral dose

Treatment:

Drug: Vadadustat

Vadadustat, Dose 3

Experimental group

Description:

Daily oral dose

Treatment:

Drug: Vadadustat

Placebo

Placebo Comparator group

Description:

Daily oral dose

Treatment:

Drug: Placebo